In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer

Cancer Science

Volumn 101, Issue 2, 2010, Pages 468-473

  Komoto, Masahiro ^a   Nakata, Bunzo ^a   Nishii, Takafumi ^a   Kawajiri, Hidemi ^a   Shinto, Osamu ^a   Amano, Ryosuke ^a   Yamada, Nobuya ^a   Yashiro, Masakazu ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG COMBINATIONS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; OXONIC ACID; PANCREATIC NEOPLASMS; QUINAZOLINES; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75649147871     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01405.x     Document Type: Article

References (26)

1. Matsuno S, Egawa S, Fukuyama S. Pancreatic cancer registry in Japan. Pancreas 2004, 28:219-30.
2. Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-13.
3. Moore MJ, Goldstein D, Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-6.
4. Herrmann R, Bodoky G, Ruhstaller T. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25:2212-7.
5. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005, 68:171-8.
6. Nakamura K, Yamaguchi T, Ishihara T. Phase I trial of S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2005, 92:2134-9.
7. Ueno H, Okusaka T, Ikeda M. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 2005, 69:421-7.
8. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006, 94:1575-9.
9. Ueno H, Okusaka T, Furuse J. A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. J Clin Oncol 2007, 25:4550.
10. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-8.
11. Konecny GE, Pegram MD, Venkatesan N. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-9.
12. Okabe T, Okamoto I, Tsukioka S. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylase synthase. Mol Cancer Ther 2008, 7:599-606.
13. Kim WY, Nakata B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and α-fluoro-β-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 2007, 98:1604-8.
14. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976, 59:253-76.
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
16. Rusnak DW, Alligood KJ, Mullin RJ. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007, 40:580-94.
17. Komoto M, Nakata B, Amano R. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 2009, 100:1243-7.
18. Yarden Y, Slimkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2:127-37.
19. Graus-Porta D, Beerli PR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-55.
20. Karunagaran D, Tzahar E, Beerli PR. ErbB-2 is a common auxiliary submit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996, 15:254-64.
21. Xia W, Mullin RJ, Keith BR. Antitumor activity of GW572016:a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21:6255-63.
22. Safran H, Miner T, Resnick T. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin. Am J Clin Oncol 2008, 31:140-4.
23. Kimura K, Sawada T, Komatsu M. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006, 12:4925-32.
24. Safran H, Iannitti D, Ramanathan R. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004, 22:706-12.
25. Wood ER, Truesdale AT, Octerlonely B. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationship among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64:6652-9.
26. Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-43.